Advertisement

Drugs in R & D

, Volume 9, Issue 2, pp 125–130 | Cite as

Mepolizumab

240563, Anti-IL-5 Monoclonal Antibody — GlaxoSmithKline, Anti-Interleukin-5 Monoclonal Antibody — GlaxoSmithKline, SB 240563
Adis R&D Profile

Keywords

Eosinophil Count Nasal Polyposis Eosinophilic Oesophagitis Hypereosinophilic Syndrome Sputum Eosinophil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. American Journal of Respiratory and Critical Care Medicine 176: 1062–1071, No. 11, 1 Dec 2007PubMedCrossRefGoogle Scholar
  2. 2.
    Cincinnati Childrens Hospital Medical Center. Cincinnati Children’ss Researchers Publish Positive Findings from Clinical Study of Investigational Treatment for Debilitating Allergic Disorder. Media Release: 20 Dec 2006. Available from URL: http://www.prnewswire.com Google Scholar
  3. 3.
    Zia-Amirhosseini P, Walls C, Patel B. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in mild asthmatics. Clinical Pharmacology and Therapeutics 65: 147, Feb 1999Google Scholar
  4. 4.
    Straumann A, Conus S, Kita H, et al. Mepolizumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic esophagitis in adults: a randomized, placebo-controlled double-blind trial. Gut 56 (Suppl. 3): 7, Oct 2007Google Scholar
  5. 5.
    Flood-Page P, Phipps S, Menzies-Gow A, et al. Effect of intravenous administration of an anti-IL-5 mAb (mepolizumab) on allergen-induced tissue eosinophilia, the late-phase allergic reaction and the expression of a marker of repair/remodeling in human atopic subjects. Journal of Allergy and Clinical Immunology 111 (Suppl.): 261 (plus poster), Feb 2003CrossRefGoogle Scholar
  6. 6.
    Menzies-Gow A, Flood-Page P, Compton C, et al. A double blind, placebo-controlled, parallel group study to assess the effect of mepolizumab (humanised monoclonal anti-IL-5 antibody) on bone marrow and peripheral blood eosinophils and eosinophil progenitors in atopic asthmatics. American Journal of Respiratory and Critical Care Medicine 165: B50, Part 2, Apr 2002Google Scholar
  7. 7.
    Phipps S, Flood-Page P, Menzies-Gow A, et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin, procollagen III and lumican in the reticular basement membrane of human atopic asthmatics. Journal of Allergy and Clinical Immunology 111 (Suppl.): 278 (plus oral presentation), Feb 2003CrossRefGoogle Scholar
  8. 8.
    Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’ss role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. American Journal of Respiratory and Critical Care Medicine 167: 199–204, 15 Jan 2003PubMedCrossRefGoogle Scholar
  9. 9.
    Weller PF, Gleich GJ, Busse WW, et al. Effects of mepolizumab, an anti-interleukin-5 monoclonal antibody, on blood eosinophil counts in patients with hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology 119 (Suppl.): 209, No. 1, Jan 2007CrossRefGoogle Scholar
  10. 10.
    Plötz S-G, Simon H-W, Darsow U, et al. Use of an antiinterleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. New England Journal of Medicine 349: 2334–2339, No. 24, 11 Dec 2003PubMedCrossRefGoogle Scholar
  11. 11.
    Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. Journal of Allergy and Clinical Immunology 113: 115–119, No. 1, Jan 2004PubMedCrossRefGoogle Scholar
  12. 12.
    Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144–2148, 23–30 Dec 2000PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Personalised recommendations